Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Evaluation of Prismocitrate 18 in CRRT
NCT05399537Phase 3Recruiting
- Sponsor
- Vanttive
- Start
- Jul 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of prismocitrate 18 in acute kidney injury (AKI), sponsored by Vanttive. Primary endpoints: Number of participants with symptomatic hypocalcemia related to Prismocitrate 18 administration, Number of participants with symptomatic hypercalcemia related to Prismocitrate 18 administration and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
prismocitrate 18
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT05399537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05399537.